SpectrumDNA Stock

SpectrumDNA ROE

The Return on Equity (ROE) of SpectrumDNA (SPXA) as of Jul 16, 2026 is -513.02 %.

ROE

-513.02 %

Last updated:

In 2026, SpectrumDNA's return on equity (ROE) was -513.02 %, a % increase from the - ROE in the previous year.

Access this data via the Eulerpool API

SpectrumDNA Stock analysis

What does SpectrumDNA do? SpectrumDNA Inc is a company specializing in the development and marketing of genetic tests and analyses. Founded in 2013, the company is based in Austin, Texas and is one of the leading companies in the field of DNA analysis. The history of SpectrumDNA goes back to its founders, Dr. Jamie Teumer and Dr. João Silveira. Both bring years of experience in genetics and molecular biology and have worked on numerous research projects. Their goal was to make genetics accessible to everyone and improve healthcare. With this drive, they founded SpectrumDNA and began to put their idea into action. SpectrumDNA's business model is based on the creation of genetic tests and analyses that allow people to know their personal risk for certain diseases or conditions and take targeted preventive measures. SpectrumDNA works closely with doctors and other healthcare experts to interpret and implement the results and recommendations of the tests. SpectrumDNA offers a variety of genetic tests and analyses targeting various areas of health and well-being. These include tests for identifying genetic risk factors for cancer, cardiovascular diseases, Alzheimer's, and Parkinson's, as well as tests for predicting behavioral traits and physical characteristics such as lactose intolerance or hair color. The company also has its own research and development department that constantly works on advancing and improving test methods and technologies. This ensures that customers at SpectrumDNA always receive the latest and most accurate information. SpectrumDNA has also specialized in developing products based on the genetic profiles of its customers. These include personalized supplements tailored to the individual needs of the customer, as well as personalized training plans based on the customer's genetic traits. Recently, SpectrumDNA has also focused its attention on the application of genetics in the beauty industry. The company has developed a procedure that allows the analysis of skin quality and aging process based on the customer's genetic profile. Based on this analysis, a personalized skincare program is created that is tailored to the individual needs and goals of the customer. Overall, SpectrumDNA is a leading company in the field of DNA analysis and specializes in personalized healthcare services. Through close collaboration with doctors and other healthcare providers, as well as constant advancement and improvement of its technologies and products, SpectrumDNA enables its customers to improve their health and well-being in a personalized and effective way. SpectrumDNA is one of the most popular companies on Eulerpool.

ROE Details

Decoding SpectrumDNA's Return on Equity (ROE)

SpectrumDNA's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing SpectrumDNA's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

SpectrumDNA's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in SpectrumDNA’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about SpectrumDNA stock

Return on Equity (ROE) of SpectrumDNA is -513.02 % in 2026.

Access this data via the Eulerpool API

Profitability — SpectrumDNA

All Key Metrics — SpectrumDNA